Methylphenidate extended release - Neos Therapeutics

Drug Profile

Methylphenidate extended release - Neos Therapeutics

Alternative Names: Cotempla XR-ODT; Methylphenidate extended-release orally disintegrating tablet; Methylphenidate XR-ODT; NT-0102

Latest Information Update: 08 May 2017

Price : $50

At a glance

  • Originator Neos Therapeutics
  • Class Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Adrenergic receptor modulators; Central nervous system stimulants; Dopamine release stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Attention-deficit hyperactivity disorder

Most Recent Events

  • 20 Mar 2017 Neos Therapeutics' extended release methylphenidate is still under Preregistration trials for Attention-deficit hyperactivity disorder (In children) in USA (PO)
  • 15 Mar 2017 Neos Therapeutics has patents protecting composition-of-matter of methylphenidate extended release in USA until 2026 and 2032
  • 14 Mar 2017 US FDA assigns PDUFA action date of 19/06/2017 for methylphenidate extended release for Attention-deficit hyperactivity disorder
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top